NREP
NEW REPRESENTATIVE AT IB RECEIVED
24/07/2023
Voltar para busca
Dado oficial do USPTO
B BRENUS PHARMA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
29
Atualização mais recente
24/07/2023
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5
Data de depósito
25/08/2020
Data de registro
23/11/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
23/11/2021
Última transação
23/11/2021
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
34
Localização do titular
FR
Examinador
BROWNE, LUCY
Unidade examinadora
N70
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the black stylized wording "BRENUS" centered above the black stylized wording "PHARMA" with a short black line extending outward from each side of the wording "PHARMA", all of which is below a design of a light blue letter "B" that is surrounded by two light blue inverted triangles superimposed over one another with one appearing larger than the other. The color white represents background, outlining, shading, and/or transparent area and is not part of the mark.
Titulares e representantes
Titulares
B. P. (pessoa física)
Representantes
Adam Weiss PatShegen IP
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical products for treating pathologies that are controllable or curable by stimulated immunological reaction from a patientthrough infectious or oncological diseases; Veterinary productsveterinary preparations for treating pathologies that are controllable or curable by stimulated immunological reaction from an animalthrough infectious or oncological diseases; Chemical preparations for pharmaceutical purposesfor treating pathologies that are controllable or curable by stimulated immunological reaction from the patientthrough infectious or oncological diseases; Biological preparations for medical or therapeutic purposespreparations for the treatment of pathologies that are controllable or curable by stimulated immunological reaction from the patientthrough infectious or oncological diseases; Biological preparations for veterinary purposespreparations for the treatment of pathologies that are controllable or curable by stimulated immunological reaction from the patientthrough infectious or oncological diseases; Pharmaceutical preparationsimmune system aids for use in human medicine; Diagnostic preparations for medical use; Diagnostic preparations for veterinary use; Immunostimulants under the pharmaceutical monopoly; medicines in the nature of vaccinal administrations for stimulating the immune system for use in human medicine; Serums under the pharmaceutical monopoly for medical purposespharmaceutical serums for the treatment of the immune system; Biocellular preparations for therapeutic or medical purposespharmaceutical preparations for the treatment of the immune system
Publicações
Histórico de despachos e eventos da marca no USPTO.
29 publicações encontradas
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
06/06/2022
FICS
FINAL DISPOSITION NOTICE SENT TO IB
12/05/2022
FIMP
FINAL DISPOSITION PROCESSED
11/05/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
23/02/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
23/11/2021
GPNX
NOTIFICATION PROCESSED BY IB
11/09/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/09/2021
PUBO
PUBLISHED FOR OPPOSITION
07/09/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
23/08/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
18/08/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
18/08/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/08/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
03/08/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
03/08/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
03/08/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
03/08/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/07/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/07/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/07/2021
RFNT
REFUSAL PROCESSED BY IB
30/01/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/01/2021
RFRR
REFUSAL PROCESSED BY MPU
09/01/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
24/12/2020
CNRT
NON-FINAL ACTION WRITTEN
23/12/2020
DOCK
ASSIGNED TO EXAMINER
23/12/2020
MAFR
APPLICATION FILING RECEIPT MAILED
03/11/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
30/10/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
29/10/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace B BRENUS PHARMA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.